English Deutsch 中文
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
Menu Deutsch 中文

Genexine Out-licenses three compounds to Tasly for $100 Million

Oct. 20, 2015

On October 20, 2015 S. Korean Genexine announced its agreement with Tasgen, a subsidiary of Tasly Pharma, according to which it has out-licensed three next-generation long-acting growth hormone compounds in a deal worth up to $100 million. Genexine will receive $20 million upfront and up to $80 million in development and commercial milestones.